

Table of Contents

1 INTRODUCTION.....	2
1.1 NEURODEGENERATIVE DISORDERS.....	2
1.2 ALZHEIMER’S DISEASE.....	2
1.3 SYMPTOMS OF ALZHEIMER’S DISEASE.....	3
1.4 STAGES OF ALZHEIMER’S DISEASE.....	3
1.5 DIAGNOSIS OF ALZHEIMER’S DISEASE.....	4
1.6 PATHOPHYSIOLOGY OF ALZHEIMER’S DISEASE.....	6
1.7 MANAGEMENT OF ALZHEIMER’S DISEASE.....	9
1.8 ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DRUG DISCOVERY.....	11
2 OBJECTIVE AND PLAN OF WORK.....	16
2.1 OBJECTIVE.....	16
2.2 PLAN OF WORK.....	16
2.2.1 <i>Classification of BACE-1 inhibitors using machine learning.....</i>	<i>16</i>
2.2.2 <i>Machine learning-based screening of in-house database for BACE-1 inhibitors.....</i>	<i>17</i>
2.2.3 <i>Natural Language Processing (NLP) for deep learning-based prediction of BBB permeability.....</i>	<i>17</i>
2.2.4 <i>Design, synthesis and biological evaluation of N-benzylpiperidines as potential multitargeted ligands for the treatment of Alzheimer’s disease.....</i>	<i>18</i>
<i>Plan of Work:.....</i>	<i>18</i>
3 CLASSIFICATION OF BACE-1 INHIBITORS USING MACHINE LEARNING METHODS.....	21
3.1 INTRODUCTION.....	21
3.2 COMPUTATIONAL METHOD.....	24
3.2.1 <i>Deriving experimental data for BACE-1 inhibitors.....</i>	<i>24</i>
3.2.2 <i>Ligand pre-treatment and preparation.....</i>	<i>25</i>
3.2.3 <i>Molecular descriptor calculation and feature selection.....</i>	<i>25</i>
3.2.4 <i>BACE-1 inhibitor training and test data sets.....</i>	<i>26</i>
3.2.5 <i>Machine learning classification algorithms.....</i>	<i>26</i>
3.2.6 <i>Validation of performance of the models.....</i>	<i>28</i>

3.2.7	<i>Comparison of the performance of models created on 2D descriptors and fingerprints with 3D descriptors</i>	28
3.3	RESULTS AND DISCUSSION.....	29
3.3.1	<i>Chemical space exploration and dataset distribution of BACE-1 inhibitors</i>	29
3.3.2	<i>Feature selection of calculated descriptors</i>	29
3.3.3	<i>BACE-1 inhibitor training, validation and test sets</i>	30
3.3.4	<i>Machine learning classification algorithms</i>	33
3.3.5	<i>Prediction of the test set data</i>	37
3.3.6	<i>Comparison of the performance of models build on 2D descriptors and fingerprints with 3D descriptors</i>	38
3.3.7	<i>Structural diversity of BACE-1 inhibitors</i>	38
3.3.8	<i>k-Means clustering of BACE-1 inhibitors</i>	39
3.3.9	<i>Comparison of performance of classification algorithms and descriptors</i>	41
3.3.10	<i>Defining applicability domain of models</i>	47
3.4	CONCLUSION	48
4	MACHINE LEARNING BASED SCREENING OF IN-HOUSE DATABASE TO IDENTIFY BACE-1 INHIBITORS	51
4.1	INTRODUCTION	51
4.1.1	<i>Sulphonamides as BACE-1 Inhibitors in Human Clinical Trials</i>	51
4.1.2	<i>Machine Learning in drug discovery</i>	53
4.1.3	<i>Machine learning algorithms</i>	54
4.2	MATERIALS AND METHODS	55
4.2.1	<i>Dataset Collection</i>	55
4.2.2	<i>Fingerprint Descriptors</i>	56
4.2.3	<i>Data Splitting</i>	56
4.2.4	<i>Machine learning classification algorithms</i>	56
4.2.5	<i>Screening Database preparation</i>	58
4.2.6	<i>BACE-1 inhibition assay</i>	58
4.2.7	<i>Docking study</i>	59
4.3	RESULT AND DISCUSSION	59

4.3.1	<i>Machine learning models</i>	59
4.3.2	<i>Performance of ML models on validation set</i>	60
4.3.3	<i>Screening of in-house library</i>	61
4.3.4	<i>In-vitro BACE-1 inhibitory activity</i>	64
4.3.5	<i>Docking study</i>	65
4.4	CONCLUSION	66
5	NATURAL-LANGUAGE PROCESSING (NLP) BASED FEATURE EXTRACTION TECHNIQUE IN DEEP-LEARNING MODEL TO PREDICT THE BLOOD-BRAIN- BARRIER PERMEABILITY OF MOLECULES	69
5.1	INTRODUCTION	69
5.2	METHODS	72
5.2.1	<i>Dataset</i>	72
5.2.2	<i>Features extractions</i>	72
5.2.3	<i>Neural Network Architecture</i>	74
5.2.4	<i>Model parameters</i>	76
5.2.5	<i>Evaluating the performance of DL models</i>	77
5.3	RESULT AND DISCUSSION	78
5.4	CONCLUSION	84
6	DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF N- BENZYLPIPERIDINES AS POTENTIAL MULTITARGETED LIGANDS FOR THE TREATMENT OF ALZHEIMER’S DISEASE	87
6.1	INTRODUCTION	87
6.2	DESIGN ASPECTS.....	89
6.3	MATERIAL AND METHODS	90
6.3.1	<i>Docking studies</i>	90
6.3.2	<i>Molecular property and toxicity prediction</i>	91
6.3.3	<i>In silico ADME property analysis</i>	91
6.3.4	<i>Synthesis and Characterization</i>	92
6.3.5	<i>In vitro studies</i>	114
6.3.6	<i>In vivo evaluation of compounds</i>	119
6.4	RESULTS AND DISCUSSION	123

6.4.1	<i>Rationale of drug design & in-silico optimization</i>	123
6.4.2	<i>Chemistry</i>	125
6.4.3	<i>Docking studies</i>	125
6.4.4	<i>Molecular property and toxicity prediction</i>	127
6.4.5	<i>In silico ADME prediction analysis</i>	127
6.4.6	<i>In-Vitro evaluation</i>	130
6.4.7	<i>In-Vivo evaluation</i>	138
6.5	CONCLUSIONS.....	145
7	SUMMARY AND CONCLUSION	148
8	REFERENCES	152